CME/CE INFORMATION

Oncology Congress

Saturday, September 28, 2024 | Live CME/CE Conference
Broadcast starts at 8:00 AM CT


HOW TO CLAIM CREDIT
In order to obtain your CME/CE certificate(s), please follow the steps below at the conclusion of the event:

  • Step 1: Log In
    Access the event here. At the upper right corner, click Login and enter your username (the email address you used to register for the event) and password.
    If you do not know your password, follow the link to reset it.
  • Step 2: Complete Evaluation(s)
    Click the Evaluations tab on the left. You will see a listing of each session. Click the blue Take Evaluation button and complete the evaluation form for each session you attended.
  • Step 3: View and Print Certificate(s)
    After you’ve completed the evaluations, click the blue Print Certificate button to view and print your CME/CE certificates.

For Pharmacists: Upon completion of the online evaluation(s), your credits will be submitted to CPE Monitor. Pharmacists have up to thirty (30) days to complete the evaluations and claim credit. Please check your NABP account within thirty (30) days to make sure the credit has posted.




Improving Equity in Endometrial Cancer Care and Treatment:
Accelerating Change to Improve Patient Outcomes in Rural and Underserved Communities


Provided by Talem Health and RME Collaborative:

custom image

ACKNOWLEDGEMENT
This initiative is co-supported by independent medical education grants from AstraZeneca Pharmaceuticals; Daiichi Sankyo, Inc.; GSK; Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.; and Pfizer, Inc. and Astellas. This session is supported by independent medical education grants from AstraZeneca Pharmaceuticals and GSK.

CREDIT AVAILABLE

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit
  • Nurses — 1.0 Contact Hour (0.75 contact hour of pharmacotherapy credit)
  • Pharmacists — 1.0 Contact Hour (0.1 CEU)

All other healthcare professionals completing this activity will be issued a statement of participation.

TARGET AUDIENCE
This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.

LEARNING OBJECTIVES

  • Describe the molecular subtypes of endometrial cancer and how these may impact prognosis and treatment
  • Evaluate clinical evidence and recommendations on evolving treatment approaches for endometrial cancer in the front-line and subsequent line setting
  • Apply multidisciplinary strategies to improve patient-centered endometrial cancer care in rural and underserved communities

FACULTY
Brian M. Slomovitz, MD, MS
Professor of Obstetrics and Gynecology
Florida International University
Director, Gynecologic Oncology
Mount Sinai Medical Center
Miami, FL

Chris Prakash, MD
Director, Quality Services - Texas Oncology
Chair, Medical Oncology Quality - Texas Oncology
President, Texas Society of Clinical Oncology
Medical Director, Texas Oncology - Paris
Paris, TX

JOINT ACCREDITATION STATEMENT

custom image

In support of improving patient care, Talem Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION
Talem Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.75 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.

CONTINUING PHARMACY EDUCATION
Talem Health designates this continuing education activity for 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008332-0000-24-054-L01-P)
Type of Activity: Application

DISCLOSURE OF CONFLICTS OF INTEREST
Talem Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All identified conflicts of interest are thoroughly vetted and mitigated according to Talem Health policy. Talem Health is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

All relevant financial relationships have been mitigated.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Brian M. Slomovitz, MD, MS, has disclosed the following relevant financial relationships: consultant/advisory board member for Aadi Bioscience, AstraZeneca Pharmaceuticals, BioNTech, Eisai, Inc., Genmab, Genentech, Inc., Gilead Sciences, Inc., GOG Foundation, GSK, Immunocore, Incyte Corporation, Karyopharm Therapeutics, Merck & Co., Inc., Myriad Genetics, Novartis Pharmaceuticals Corporation, Novocure, Regeneron Pharmaceuticals, Inc., and Seagen.

Chris Prakash, MD, has disclosed the following relevant financial relationships: speakers’ bureau/honoraria from Myriad Genetics, Inc.

Planners, Managers, and Reviewer
The Talem Health planners, managers, and reviewer have nothing to disclose.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.




Evolving Treatment Options in First-Line Metastatic Urothelial Carcinoma:
Integrating the Latest Guidance and Evidence in Rural and Underserved Communities


Provided by Talem Health and RME Collaborative:

custom image

ACKNOWLEDGEMENT
This initiative is co-supported by independent medical education grants from AstraZeneca Pharmaceuticals; Daiichi Sankyo, Inc.; GSK; Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.; Pfizer, Inc. and Astellas. This session is supported by independent medical education grants from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.; and Pfizer, Inc. and Astellas.

CREDIT AVAILABLE

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit
  • Nurses — 1.0 Contact Hour (0.75 contact hour of pharmacotherapy credit)
  • Pharmacists — 1.0 Contact Hour (0.1 CEU)

All other healthcare professionals completing this activity will be issued a statement of participation.

TARGET AUDIENCE
This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.

LEARNING OBJECTIVES

  • Evaluate clinical data for safety and efficacy of novel and emerging monotherapy and combination approaches for first-line treatment of metastatic and locally advanced urothelial carcinoma
  • Apply evidence-based recommendations to recognize, monitor, and mitigate adverse events associated with new and emerging treatment strategies for metastatic and locally advanced urothelial carcinoma in the first-line setting
  • Employ interprofessional strategies to enhance care coordination and shared decision-making for patients with urothelial carcinoma

FACULTY
Daniel P. Petrylak, MD
Professor of Medicine (Medical Oncology) and Urology
Yale School of Medicine
Chief, Genitourinary Oncology
Yale Cancer Center
New Haven, CT

Chris Prakash, MD
Director, Quality Services - Texas Oncology
Chair, Medical Oncology Quality - Texas Oncology
President, Texas Society of Clinical Oncology
Medical Director, Texas Oncology - Paris
Paris, TX

JOINT ACCREDITATION STATEMENT

custom image

In support of improving patient care, Talem Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION
Talem Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.75 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.

CONTINUING PHARMACY EDUCATION
Talem Health designates this continuing education activity for 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008332-0000-24-066-L01-P)
Type of Activity: Application

DISCLOSURE OF CONFLICTS OF INTEREST
Talem Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All identified conflicts of interest are thoroughly vetted and mitigated according to Talem Health policy. Talem Health is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

All relevant financial relationships have been mitigated.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Daniel P. Petrylak, MD, has disclosed the following relevant financial relationships: consultant/advisory board member for Astellas Pharma, Inc., Bayer, Bicycle Therapeutics, Bristol Myers Squibb, Corbus Pharmaceuticals Holdings, Inc., EMD Serono, Inc., Exelixis, Inc., Gilead Sciences, Inc., Janssen Pharmceuticals, Lantheus Holdings, Inc., Merck & Co., Inc., Pfizer, Inc., Sanofi-Aventis, and Seagen, Inc.; grant/research support from Amgen, Inc., Arvinas, Inc., Astellas Pharma, Inc., AstraZeneca, Bicycle Therapeutics, Flare Therapeutics, Gilead Sciences, Inc., Merck & Co., Inc., and Seagen, Inc.

Chris Prakash, MD, has disclosed the following relevant financial relationships: speakers’ bureau/honoraria from Myriad Genetics, Inc.

Planners, Managers, and Reviewer
The Talem Health planners, managers, and reviewer have nothing to disclose.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.




Evolving Treatment Paradigms in HR+/HER2- Early Breast Cancer:
Advancing Equitable Care in Rural and Underserved Communities


Provided by Talem Health and RME Collaborative:

custom image

ACKNOWLEDGEMENT
This initiative is co-supported by independent medical education grants from AstraZeneca Pharmaceuticals; Daiichi Sankyo, Inc.; GSK; Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.; Pfizer, Inc. and Astellas. This session is supported by independent medical education grants from AstraZeneca Pharmaceuticals and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.

CREDIT AVAILABLE

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit
  • Nurses — 1.0 Contact Hour (0.75 contact hour of pharmacotherapy credit)
  • Pharmacists — 1.0 Contact Hour (0.1 CEU)

All other healthcare professionals completing this activity will be issued a statement of participation.

TARGET AUDIENCE
This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.

LEARNING OBJECTIVES

  • Integrate clinical evidence and current guidance on biomarker and genetic testing into management of HR+/HER2- early breast cancer
  • Evaluate the efficacy and safety of current and emerging therapies for HR+/HER2- early breast cancer
  • Develop personalized treatment plans for patients with HR+/HER2- early breast cancer based on patient and disease characteristics
  • Discuss interprofessional strategies for improving early breast cancer care and management in rural and underserved settings

FACULTY
Harold J. Burstein, MD, PhD

Professor of Medicine
Harvard Medical School
Medical Oncologist
Dana-Farber Cancer Institute
Boston, MA

Chris Prakash, MD
Director, Quality Services - Texas Oncology
Chair, Medical Oncology Quality - Texas Oncology
President, Texas Society of Clinical Oncology
Medical Director, Texas Oncology - Paris
Paris, TX

JOINT ACCREDITATION STATEMENT

custom image

In support of improving patient care, Talem Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION
Talem Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.75 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.

CONTINUING PHARMACY EDUCATION
Talem Health designates this continuing education activity for 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008332-0000-24-052-L01-P)
Type of Activity: Application

DISCLOSURE OF CONFLICTS OF INTEREST
Talem Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All identified conflicts of interest are thoroughly vetted and mitigated according to Talem Health policy. Talem Health is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

All relevant financial relationships have been mitigated.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Harold J. Burstein, MD, PhD
, has no relevant financial relationships to disclose.

Chris Prakash, MD, has disclosed the following relevant financial relationships: speakers’ bureau/honoraria from Myriad Genetics, Inc.

Planners, Managers, and Reviewer
The Talem Health planners, managers, and reviewer have nothing to disclose.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.



Targeting the PI3K/AKT/PTEN Pathway for Treatment of Breast Cancer:
Innovative Solutions for Equitable Care


Provided by Talem Health and RME Collaborative:

custom image

ACKNOWLEDGEMENT
This initiative is co-supported by independent medical education grants from AstraZeneca Pharmaceuticals; Daiichi Sankyo, Inc.; GSK; Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.; Pfizer, Inc. and Astellas. This session is supported by an independent medical education grant from AstraZeneca Pharmaceuticals.

CREDIT AVAILABLE

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit
  • Nurses — 1.0 Contact Hour (0.75 contact hour of pharmacotherapy credit)
  • Pharmacists — 1.0 Contact Hour (0.1 CEU)

All other healthcare professionals completing this activity will be issued a statement of participation.

TARGET AUDIENCE
This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.

LEARNING OBJECTIVES

  • Evaluate the efficacy and safety of current and emerging treatments for breast cancer that target the PI3K/AKT/PTEN pathway
  • Identify patients who may be eligible for treatment with inhibitors of the PI3K/AKT/PTEN pathway
  • Apply evidence-based strategies and best practices to identify, monitor, and manage adverse events associated with PI3K/AKT/PTEN pathway inhibitors
  • Develop a multidisciplinary approach to improve treatment adherence and care coordination in breast cancer, considering the unique challenges faced by rural and underserved populations

FACULTY
Harold J. Burstein, MD, PhD
Professor of Medicine
Harvard Medical School
Medical Oncologist
Dana-Farber Cancer Institute
Boston, MA

Chris Prakash, MD
Director, Quality Services - Texas Oncology
Chair, Medical Oncology Quality - Texas Oncology
President, Texas Society of Clinical Oncology
Medical Director, Texas Oncology - Paris
Paris, TX

JOINT ACCREDITATION STATEMENT

custom image

In support of improving patient care, Talem Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION
Talem Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.75 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.

CONTINUING PHARMACY EDUCATION
Talem Health designates this continuing education activity for 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008332-0000-24-065-L01-P)
Type of Activity: Application

DISCLOSURE OF CONFLICTS OF INTEREST
Talem Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All identified conflicts of interest are thoroughly vetted and mitigated according to Talem Health policy. Talem Health is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

All relevant financial relationships have been mitigated.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Harold J. Burstein, MD, PhD, has no relevant financial relationships to disclose.

Chris Prakash, MD, has disclosed the following relevant financial relationships: speakers’ bureau/honoraria from Myriad Genetics, Inc.

Planners, Managers, and Reviewer
The Talem Health planners, managers, and reviewer have nothing to disclose.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.



Optimizing Melanoma Outcomes in Rural and Underserved Communities:
Adapting to Evolving Treatment Paradigms


Provided by Talem Health and RME Collaborative:

custom image

ACKNOWLEDGEMENT
This initiative is co-supported by independent medical education grants from AstraZeneca Pharmaceuticals; Daiichi Sankyo, Inc.; GSK; Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.; Pfizer, Inc. and Astellas. This session is supported by an independent medical education grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.

CREDIT AVAILABLE

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit
  • Nurses — 1.0 Contact Hour (0.75 contact hour of pharmacotherapy credit)
  • Pharmacists — 1.0 Contact Hour (0.1 CEU)

All other healthcare professionals completing this activity will be issued a statement of participation.

TARGET AUDIENCE
This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.

LEARNING OBJECTIVES

  • Apply evidence-based strategies for reducing melanoma care disparities in in rural and underserved communities
  • Incorporate current guideline recommendations and clinical trial data to personalize treatment of advanced melanoma in patients from rural and underserved areas
  • Employ a patient-centered approach for preventing, monitoring, and mitigating adverse events related to treatment for advanced melanoma, considering the unique challenges for rural and underserved settings

FACULTY
David M. Miller, MD, PhD
Assistant Professor of Medicine and Dermatology
Harvard Medical School
Director, Center for Merkel Cell Carcinoma
Co-Director, NMSC Multi-Disciplinary Clinic
Massachusetts General Hospital
Boston, MA

Chris Prakash, MD
Director, Quality Services - Texas Oncology
Chair, Medical Oncology Quality - Texas Oncology
President, Texas Society of Clinical Oncology
Medical Director, Texas Oncology - Paris
Paris, TX

JOINT ACCREDITATION STATEMENT

custom image

In support of improving patient care, Talem Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION
Talem Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.75 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.

CONTINUING PHARMACY EDUCATION
Talem Health designates this continuing education activity for 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008332-0000-24-060-L01-P)
Type of Activity: Application

DISCLOSURE OF CONFLICTS OF INTEREST
Talem Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All identified conflicts of interest are thoroughly vetted and mitigated according to Talem Health policy. Talem Health is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

All relevant financial relationships have been mitigated.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
David M. Miller, MD, PhD, has disclosed the following relevant financial relationships: advisory board member for Almirall, LLC, Bristol Myers Squibb, Castle Biosciences, Checkpoint Therapeutics, EMD Serono, Inc., Merck & Co., Inc., Pfizer, Inc., Regeneron Pharmaceuticals, Inc., and Sanofi Genzyme; research/grant support from the American Skin Association, ECOG-ACRIN Cancer Research Group, Kartos Therapeutics, NeoImmuneTech, Inc., Project Data Sphere, and Regeneron Pharmaceuticals, Inc.; ownership/stock options from Avstera Therapeutics and Checkpoint Therapeutics.

Chris Prakash, MD, has disclosed the following relevant financial relationships: speakers’ bureau/honoraria from Myriad Genetics, Inc.

Planners, Managers, and Reviewer
The Talem Health planners, managers, and reviewer have nothing to disclose.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.



Updates in Non-Small Cell Lung Cancer From 2024 WCLC and ESMO


Provided by Talem Health and RME Collaborative:

custom image

ACKNOWLEDGEMENT
This initiative is co-supported by independent medical education grants from AstraZeneca Pharmaceuticals; Daiichi Sankyo, Inc.; GSK; Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.; Pfizer, Inc. and Astellas. This session is supported by independent medical education grants from AstraZeneca Pharmaceuticals, Daiichi Sankyo, Inc., and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.

CREDIT AVAILABLE

  • Physicians — maximum of 1.25 AMA PRA Category 1 Credits
  • Nurses — 1.25 Contact Hours (1.0 contact hour of pharmacotherapy credit)
  • Pharmacists — 1.25 Contact Hours (0.125 CEUs)

All other healthcare professionals completing this activity will be issued a statement of participation.

TARGET AUDIENCE
This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.

LEARNING OBJECTIVES

  • Evaluate new data on novel agents and therapeutic strategies for patients with NSCLC
  • Discuss how new clinical trial findings may affect treatment of patients with advanced NSCLC
  • Apply recently presented data and expert recommendations to optimize care for patients with NSCLC

FACULTY
Rebecca S. Heist, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Chair, Clinical Cancer Research
Massachusetts General Hospital Cancer Center
Boston, MA

Chris Prakash, MD
Director, Quality Services - Texas Oncology
Chair, Medical Oncology Quality - Texas Oncology
President, Texas Society of Clinical Oncology
Medical Director, Texas Oncology - Paris
Paris, TX

JOINT ACCREDITATION STATEMENT

custom image

In support of improving patient care, Talem Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION
Talem Health designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.25 contact hours. Designated for 1.0 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.

CONTINUING PHARMACY EDUCATION
Talem Health designates this continuing education activity for 1.25 contact hours (0.125 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008332-0000-24-062-L01-P)
Type of Activity: Application

DISCLOSURE OF CONFLICTS OF INTEREST
Talem Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All identified conflicts of interest are thoroughly vetted and mitigated according to Talem Health policy. Talem Health is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

All relevant financial relationships have been mitigated.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Rebecca S. Heist, MD, MPH, has disclosed the following relevant financial relationships: consultant/advisory board member for AbbVie, Inc., Amgen, Inc., AstraZeneca Pharmaceuticals, Biohaven, Ltd., Daiichi Sankyo, Inc., CLaiM Therapeutics, Eli Lilly and Company, Genentech, Inc./Roche, Gilead Sciences, Inc., Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc., and Sanofi; research/grant support (awarded to institution) for AbbVie, Inc., Agios Pharmaceuticals, Corvus Pharmaceuticals, Daiichi Sankyo, Inc., Erasca, Inc., Eli Lilly and Company, Mirati Therapeutics, Inc., Novartis Pharmaceuticals Corporation, and Turning Point Therapeutics, Inc. (now Bristol Myers Squibb).

Chris Prakash, MD, has disclosed the following relevant financial relationships: speakers’ bureau/honoraria from Myriad Genetics, Inc.

Planners, Managers, and Reviewer
The Talem Health planners, managers, and reviewer have nothing to disclose.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.



CONTACT US

For questions about this activity, please contact RME Collaborative (a division of Talem Health) at 800-913-9370 or cme@cmeruralhealth.com.

MEDIA
Internet activity

COMPUTER SYSTEM REQUIREMENTS

  • System checker: Must meet all requirements of BroadcastMed Live Events Platform
  • Operating system: Windows or Macintosh
  • Supported browsers: HTML5-capable browser – Internet Explorer, Google Chrome, Mozilla Firefox, Safari, Microsoft Edge, Opera
  • Hardware: computer, smartphone, or tablet
  • Broadband Internet connection: high-speed connection preferable

FEE INFORMATION
There is no fee for this educational activity.

COPYRIGHT
©RME Collaborative, a division of Talem Health, LLC. All Rights Reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Talem Health, LLC is prohibited.